China Intravenous Immunoglobulin Market Size & Outlook
China intravenous immunoglobulin market, 2018-2030 (US$M)
Related Markets
China intravenous immunoglobulin market highlights
- The China intravenous immunoglobulin market generated a revenue of USD 637.2 million in 2024 and is expected to reach USD 1,078.8 million by 2030.
- The China market is expected to grow at a CAGR of 9.1% from 2025 to 2030.
- In terms of segment, hypogammaglobulinemia was the largest revenue generating application in 2024.
- Kawasaki Disease is the most lucrative application segment registering the fastest growth during the forecast period.
Intravenous immunoglobulin market data book summary
| Market revenue in 2024 | USD 637.2 million |
| Market revenue in 2030 | USD 1,078.8 million |
| Growth rate | 9.1% (CAGR from 2025 to 2030) |
| Largest segment | Hypogammaglobulinemia |
| Fastest growing segment | Kawasaki Disease |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome |
| Key market players worldwide | Biotest AG ADR, Baxter International Inc, Grifols SA Ordinary Shares - Class A, CSL Ltd, Octapharma AG, LFB (Laboratoire Français du Fractionnement et des Biotechnologies), Taibang Biological Group, Kedrion Biopharma |
Other key industry trends
- In terms of revenue, China accounted for 4.6% of the global intravenous immunoglobulin market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan intravenous immunoglobulin market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,078.8 million by 2030.
Hypogammaglobulinemia was the largest segment with a revenue share of 21.44% in 2024. Horizon Databook has segmented the China intravenous immunoglobulin market based on immunodeficiency diseases, cidp, hypogammaglobulinemia, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, itp, kawasaki disease, guillain-barre syndrome covering the revenue growth of each sub-segment from 2018 to 2030.
The Intravenous Immunoglobulin (IVIG) market in China is witnessing rapid growth, primarily driven by the increasing incidence of immunodeficiency diseases such as Chronic Lymphocytic Leukemia, ITP, and Hypogammaglobulinemia. Urbanization and increased access to healthcare services are contributing to the demand for advanced IVIG treatments, which are primarily distributed through hospital and specialty pharmacies. Major players like China Biologics Products Inc. and Kedrion are expanding their market presence in China to capitalize on this growth opportunity.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Immunoglobulin Market Scope
Intravenous Immunoglobulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China intravenous immunoglobulin market size, by application, 2018-2030 (US$M)
China Intravenous Immunoglobulin Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
